833 abstracts found.



Results filter

Quantifying the costs of colorectal cancer: the importance of considering different perspectives

Year:

Session type:

Paul Hanly1, Alan O'Ceilleachair1, Mairead Skally1, Ciaran O'Neill2, Kanika Kapur3, Patricia Fitzpatrick3, Anthony Staines4, Linda Sharp1
1National Cancer Registry, Cork, Ireland, 2National University of Ireland, Galway, Ireland, 3University College Dublin, Dublin, Ireland, 4Dublin City University, Dublin, Ireland

Using the National Cancer Data Repository to measure long term clinical outcomes – data from the MRC CR07 trial

Year:

Session type:

Eva Morris1,3, Louise Whitehouse1,3, James Thomas2, Phil Quirke1, Lindsay Thompson2, John Wilkinson3, David Sebag-Montefiore1
1University of Leeds, Leeds, UK, 2MRC Clinical Trial Unit, London, UK, 3Northern & Yorkshire Cancer Registry & Information Service, Leeds, UK

A novel method for the high resolution, genome-wide analysis of DNA damage induced by platinum analogue chemotherapy agents – a technology to aid patient stratification

Year:

Session type:

James Powell1, Mark Bennett1, Raymond Waters1, Simon Reed1
1Institute of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, UK

Lessons to learn – breast cancer treatment – an institutional experience from a developing country

Year:

Session type:

Nasir Afsar1, Bibi Kulsoom1, Ahmed Mateen2, Saeed Ahmed2, Mahwish Tahseen2, Adeel Ahmed2
1Alfaisal University, Riyadh, Saudi Arabia, 2Karachi Institute of Radiotherapy and Nuclear Medicine, Karachi, Pakistan

A genome-wide study of histone H3 acetylation in response to platinum analogue treatment – can the epigenome provide a novel approach to patient stratification?

Year:

Session type:

James Powell1, Mark Bennett1, Raymond Waters1, Simon Reed1
1Institute of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, UK

Are patients interested in clinical trials? An update from CancerHelp UK

Year:

Session type:

Claire Connolly1, Liz Woolf1
1Cancer Research UK, London, UK

Prognostic significance of hypoxia-inducible factor-1α and vascular endothelial growth factor expression in patients with diffuse large B-cell lymphoma treated with rituximab

Year:

Session type:

James Powell1, Stefan Dojcinov2, Louise King2, Sue Wosniak2, Stephen Gerry3, Angela Casbard3, Hazel Bailey1, Eve Gallop-Evans1, Tim Maughan4
1Velindre Cancer Centre, Cardiff, UK, 2University Hospital of Wales, Cardiff, UK, 3Wales Cancer Trials Unit, Cardiff, UK, 4Gray Institute for Radiation Oncology & Biology, University of Oxford, Oxford, UK

Molecular mechanisms that determine the response of glioblastomas to phosphatidylinositol-3 kinase inhibitors

Year:

Session type:

Christopher Milton1, Paul Clarke1, Paul Workman1
1The Institute of Cancer Research, Sutton, UK

A Cancer Research UK Phase I Trial of Phortress (Novel Antitumour Benzothiazole) Given Intravenously in Consecutive 21 Day Cycles with Treatment on Day 1 of Each Cycle

Year:

Session type:

Michael Seckl2, Nicola Cresti1, Alan Boddy1, Roger Phillips6, Fiona Chapman1, Peter Schmid5, Hilary Calvert3, Lesley Robson4, Ruth Plummer1
1Newcastle University, Newcastle upon Tyne, UK, 2Imperial College, London, UK, 3University College London, London, UK, 4DDO, Cancer Research UK, London, UK, 5University of Sussex, Brighton, UK, 6Bradford University, Bradford, UK

Identification of breast cancer biomarkers as therapeutic and diagnostic agents using in-silico and molecular approaches

Year:

Session type:

Nosipho Ngcoza1, Mervin Meyer1, Ashley Pretorius1
1University of the Western Cape, Cape Town, South Africa

Page 25 of 84« First...25...50...Last »